These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 32203145)

  • 81. Fingolimod increases CD39-expressing regulatory T cells in multiple sclerosis patients.
    Muls N; Dang HA; Sindic CJ; van Pesch V
    PLoS One; 2014; 9(11):e113025. PubMed ID: 25411844
    [TBL] [Abstract][Full Text] [Related]  

  • 82. CD8+CD103+ iTregs Inhibit Chronic Graft-versus-Host Disease with Lupus Nephritis by the Increased Expression of CD39.
    Zhang X; Ouyang X; Xu Z; Chen J; Huang Q; Liu Y; Xu T; Wang J; Olsen N; Xu A; Zheng SG
    Mol Ther; 2019 Nov; 27(11):1963-1973. PubMed ID: 31402273
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Purinergic signaling during intestinal inflammation.
    Longhi MS; Moss A; Jiang ZG; Robson SC
    J Mol Med (Berl); 2017 Sep; 95(9):915-925. PubMed ID: 28547076
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Autocrine Adenosine Regulates Tumor Polyfunctional CD73
    Gourdin N; Bossennec M; Rodriguez C; Vigano S; Machon C; Jandus C; Bauché D; Faget J; Durand I; Chopin N; Tredan O; Marie JC; Dubois B; Guitton J; Romero P; Caux C; Ménétrier-Caux C
    Cancer Res; 2018 Jul; 78(13):3604-3618. PubMed ID: 29559470
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Platelets induce CD39 expression in tumor cells to facilitate tumor metastasis.
    Ning Z; Liu K; Zhang H; Dong G; Wang X; Xiong H
    Br J Cancer; 2024 May; 130(9):1542-1551. PubMed ID: 38461171
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Endogenous antisense RNA curbs CD39 expression in Crohn's disease.
    Harshe RP; Xie A; Vuerich M; Frank LA; Gromova B; Zhang H; Robles RJ; Mukherjee S; Csizmadia E; Kokkotou E; Cheifetz AS; Moss AC; Kota SK; Robson SC; Longhi MS
    Nat Commun; 2020 Nov; 11(1):5894. PubMed ID: 33208731
    [TBL] [Abstract][Full Text] [Related]  

  • 87. CD39 - A bright target for cancer immunotherapy.
    Guo S; Han F; Zhu W
    Biomed Pharmacother; 2022 Jul; 151():113066. PubMed ID: 35550530
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The protective effects of CD39 overexpression in multiple low-dose streptozotocin-induced diabetes in mice.
    Chia JS; McRae JL; Thomas HE; Fynch S; Elkerbout L; Hill P; Murray-Segal L; Robson SC; Chen JF; d'Apice AJ; Cowan PJ; Dwyer KM
    Diabetes; 2013 Jun; 62(6):2026-35. PubMed ID: 23364452
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Targeting CD39 in cancer.
    Moesta AK; Li XY; Smyth MJ
    Nat Rev Immunol; 2020 Dec; 20(12):739-755. PubMed ID: 32728220
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Sepsis expands a CD39
    Nascimento DC; Viacava PR; Ferreira RG; Damaceno MA; Piñeros AR; Melo PH; Donate PB; Toller-Kawahisa JE; Zoppi D; Veras FP; Peres RS; Menezes-Silva L; Caetité D; Oliveira AER; Castro ÍMS; Kauffenstein G; Nakaya HI; Borges MC; Zamboni DS; Fonseca DM; Paschoal JAR; Cunha TM; Quesniaux V; Linden J; Cunha FQ; Ryffel B; Alves-Filho JC
    Immunity; 2021 Sep; 54(9):2024-2041.e8. PubMed ID: 34473957
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Increased host ATP efflux and its conversion to extracellular adenosine is crucial for establishing
    Basu M; Gupta P; Dutta A; Jana K; Ukil A
    J Cell Sci; 2020 Apr; 133(7):. PubMed ID: 32079656
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Genetic analysis of an allergic rhinitis cohort reveals an intercellular epistasis between FAM134B and CD39.
    Melchiotti R; Puan KJ; Andiappan AK; Poh TY; Starke M; Zhuang L; Petsch K; Lai TS; Chew FT; Larbi A; Wang de Y; Poidinger M; Rotzschke O
    BMC Med Genet; 2014 Jun; 15():73. PubMed ID: 24970562
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Genomic landscape of young ATLL patients identifies frequent targetable CD28 fusions.
    Yoshida N; Shigemori K; Donaldson N; Trevisani C; Cordero NA; Stevenson KE; Bu X; Arakawa F; Takeuchi M; Ohshima K; Yoda A; Ng SY; Weinstock DM
    Blood; 2020 Apr; 135(17):1467-1471. PubMed ID: 31961925
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Glycoengineered anti-CD39 promotes anticancer responses by depleting suppressive cells and inhibiting angiogenesis in tumor models.
    Zhang H; Feng L; de Andrade Mello P; Mao C; Near R; Csizmadia E; Chan LL; Enjyoji K; Gao W; Zhao H; Robson SC
    J Clin Invest; 2022 Jul; 132(13):. PubMed ID: 35775486
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Hippocampal CD39/ENTPD1 promotes mouse depression-like behavior through hydrolyzing extracellular ATP.
    Cui QQ; Hu ZL; Hu YL; Chen X; Wang J; Mao L; Lu XJ; Ni M; Chen JG; Wang F
    EMBO Rep; 2020 Apr; 21(4):e47857. PubMed ID: 32133764
    [TBL] [Abstract][Full Text] [Related]  

  • 96. PLA2G4A promotes right-sided colorectal cancer progression by inducing CD39+γδ Treg polarization.
    Zhan Y; Zheng L; Liu J; Hu D; Wang J; Liu K; Guo J; Zhang T; Kong D
    JCI Insight; 2021 Aug; 6(16):. PubMed ID: 34283812
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Clinicopathological features of adult T-cell leukemia/lymphoma with T-follicular helper phenotype.
    Muto R; Miyoshi H; Nakashima K; Takeuchi M; Hamasaki M; Ohshima K
    Cancer Med; 2024 Mar; 13(6):e7050. PubMed ID: 38506241
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39.
    Takenaka MC; Gabriely G; Rothhammer V; Mascanfroni ID; Wheeler MA; Chao CC; Gutiérrez-Vázquez C; Kenison J; Tjon EC; Barroso A; Vandeventer T; de Lima KA; Rothweiler S; Mayo L; Ghannam S; Zandee S; Healy L; Sherr D; Farez MF; Prat A; Antel J; Reardon DA; Zhang H; Robson SC; Getz G; Weiner HL; Quintana FJ
    Nat Neurosci; 2019 May; 22(5):729-740. PubMed ID: 30962630
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Genetically Driven CD39 Expression Affects Sezary Cell Viability and IL-2 Production and Detects Two Patient Subsets with Distinct Prognosis.
    Picozza M; Cristofoletti C; Bresin A; Fioretti M; Sambucci M; Scala E; Monopoli A; Cantonetti M; Pilla MA; Accetturi MP; Borsellino G; D'Atri S; Caprini E; Russo G; Narducci MG
    J Invest Dermatol; 2022 Nov; 142(11):3009-3019.e9. PubMed ID: 35533722
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Cancer CD39 drives metabolic adaption and mal-differentiation of CD4
    Wang Y; Liu M; Zhang L; Liu X; Ji H; Wang Y; Gui J; Yue Y; Wen Z
    Cell Death Dis; 2023 Dec; 14(12):804. PubMed ID: 38062068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.